Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 88074 | 3.205 |
09:34 ET | 13223 | 3.2 |
09:36 ET | 6678 | 3.215 |
09:38 ET | 53382 | 3.17 |
09:39 ET | 11578 | 3.155 |
09:41 ET | 4267 | 3.13 |
09:43 ET | 15469 | 3.09 |
09:45 ET | 15411 | 3.07 |
09:48 ET | 1129 | 3.08 |
09:50 ET | 8853 | 3.0606 |
09:52 ET | 10959 | 3.08 |
09:54 ET | 3443 | 3.08 |
09:56 ET | 2802 | 3.095 |
09:57 ET | 20740 | 3.12 |
09:59 ET | 2662 | 3.11 |
10:01 ET | 10930 | 3.13 |
10:03 ET | 3402 | 3.13 |
10:06 ET | 5525 | 3.12 |
10:08 ET | 10691 | 3.15 |
10:10 ET | 4399 | 3.125 |
10:12 ET | 8669 | 3.135 |
10:14 ET | 11637 | 3.15 |
10:15 ET | 27771 | 3.125 |
10:17 ET | 6474 | 3.1094 |
10:19 ET | 7186 | 3.115 |
10:21 ET | 1000 | 3.115 |
10:24 ET | 3800 | 3.125 |
10:26 ET | 400 | 3.13 |
10:28 ET | 16761 | 3.11 |
10:30 ET | 2306 | 3.105 |
10:32 ET | 6196 | 3.095 |
10:33 ET | 626 | 3.1 |
10:35 ET | 1207 | 3.1 |
10:37 ET | 12330 | 3.085 |
10:39 ET | 100 | 3.085 |
10:42 ET | 5863 | 3.09 |
10:44 ET | 126 | 3.09 |
10:46 ET | 3543 | 3.095 |
10:48 ET | 11313 | 3.115 |
10:50 ET | 300 | 3.115 |
10:51 ET | 13258 | 3.11 |
10:53 ET | 639 | 3.105 |
10:55 ET | 5121 | 3.11 |
10:57 ET | 1000 | 3.11 |
11:00 ET | 15946 | 3.135 |
11:02 ET | 7249 | 3.1199 |
11:04 ET | 774 | 3.115 |
11:06 ET | 4493 | 3.1 |
11:08 ET | 17030 | 3.105 |
11:09 ET | 2729 | 3.095 |
11:11 ET | 4000 | 3.105 |
11:13 ET | 2653 | 3.095 |
11:15 ET | 4085 | 3.085 |
11:18 ET | 1752 | 3.09 |
11:20 ET | 1300 | 3.09 |
11:22 ET | 740 | 3.09 |
11:24 ET | 900 | 3.085 |
11:26 ET | 4621 | 3.085 |
11:27 ET | 9762 | 3.085 |
11:29 ET | 207 | 3.085 |
11:31 ET | 700 | 3.09 |
11:33 ET | 14972 | 3.1 |
11:36 ET | 1000 | 3.095 |
11:38 ET | 7158 | 3.095 |
11:40 ET | 4789 | 3.085 |
11:42 ET | 900 | 3.09 |
11:44 ET | 3017 | 3.085 |
11:45 ET | 8934 | 3.065 |
11:47 ET | 200 | 3.065 |
11:49 ET | 100 | 3.065 |
11:51 ET | 20472 | 3.085 |
11:54 ET | 1957 | 3.09 |
11:56 ET | 5379 | 3.085 |
11:58 ET | 5400 | 3.065 |
12:00 ET | 890 | 3.065 |
12:02 ET | 3509 | 3.065 |
12:03 ET | 648 | 3.065 |
12:05 ET | 9166 | 3.055 |
12:07 ET | 5841 | 3.065 |
12:09 ET | 548 | 3.065 |
12:12 ET | 1300 | 3.07 |
12:14 ET | 400 | 3.07 |
12:16 ET | 830 | 3.065 |
12:18 ET | 11970 | 3.055 |
12:20 ET | 7782 | 3.045 |
12:21 ET | 844 | 3.045 |
12:23 ET | 100 | 3.045 |
12:25 ET | 1900 | 3.045 |
12:27 ET | 12541 | 3.045 |
12:30 ET | 4044 | 3.04 |
12:32 ET | 985 | 3.035 |
12:34 ET | 2212 | 3.035 |
12:38 ET | 1165 | 3.04 |
12:39 ET | 5180 | 3.045 |
12:41 ET | 1188 | 3.045 |
12:43 ET | 600 | 3.05 |
12:45 ET | 909 | 3.05 |
12:48 ET | 10110 | 3.025 |
12:50 ET | 7144 | 3.02 |
12:52 ET | 1485 | 3.015 |
12:54 ET | 400 | 3.015 |
12:56 ET | 600 | 3.015 |
12:57 ET | 585 | 3.015 |
12:59 ET | 1085 | 3.02 |
01:01 ET | 500 | 3.015 |
01:03 ET | 1085 | 3.015 |
01:06 ET | 585 | 3.015 |
01:08 ET | 500 | 3.015 |
01:10 ET | 7617 | 3.025 |
01:12 ET | 6989 | 3.015 |
01:14 ET | 478 | 3.015 |
01:15 ET | 8261 | 3 |
01:17 ET | 1037 | 3.005 |
01:19 ET | 100 | 3.005 |
01:21 ET | 3117 | 3.005 |
01:24 ET | 14533 | 3 |
01:26 ET | 6255 | 3.005 |
01:28 ET | 2407 | 3 |
01:30 ET | 300 | 3.005 |
01:32 ET | 1400 | 3 |
01:33 ET | 600 | 3.01 |
01:35 ET | 1700 | 3.005 |
01:37 ET | 9283 | 3.025 |
01:39 ET | 5599 | 3.015 |
01:42 ET | 2811 | 3.005 |
01:44 ET | 600 | 3.005 |
01:46 ET | 632 | 3.01 |
01:48 ET | 6100 | 3.01 |
01:51 ET | 600 | 3.005 |
01:53 ET | 1200 | 3.005 |
01:55 ET | 1200 | 3.01 |
01:57 ET | 3100 | 3.005 |
02:00 ET | 2461 | 2.995 |
02:02 ET | 500 | 2.995 |
02:04 ET | 700 | 3 |
02:06 ET | 3000 | 3.005 |
02:08 ET | 1900 | 3.01 |
02:09 ET | 2919 | 3 |
02:11 ET | 600 | 3 |
02:13 ET | 1267 | 3.005 |
02:15 ET | 2200 | 3 |
02:18 ET | 3027 | 2.995 |
02:20 ET | 1344 | 3 |
02:22 ET | 400 | 3 |
02:24 ET | 1000 | 3 |
02:26 ET | 300 | 3 |
02:27 ET | 8311 | 2.995 |
02:29 ET | 527 | 2.995 |
02:31 ET | 2214 | 2.995 |
02:33 ET | 1200 | 3 |
02:36 ET | 2700 | 2.9999 |
02:38 ET | 2275 | 3 |
02:40 ET | 1867 | 2.995 |
02:42 ET | 8324 | 2.995 |
02:44 ET | 4225 | 2.995 |
02:45 ET | 7822 | 3 |
02:47 ET | 3227 | 3 |
02:49 ET | 2443 | 2.99 |
02:51 ET | 1808 | 3 |
02:54 ET | 3379 | 3.005 |
02:56 ET | 7264 | 3 |
02:58 ET | 5143 | 2.99 |
03:00 ET | 2418 | 2.995 |
03:02 ET | 1139 | 2.995 |
03:03 ET | 1100 | 2.995 |
03:05 ET | 700 | 2.99 |
03:07 ET | 2544 | 2.995 |
03:09 ET | 1000 | 2.99 |
03:12 ET | 500 | 2.995 |
03:14 ET | 8795 | 3.005 |
03:16 ET | 6987 | 3 |
03:18 ET | 3157 | 2.99 |
03:20 ET | 1935 | 2.99 |
03:21 ET | 2231 | 2.995 |
03:23 ET | 6129 | 3.005 |
03:25 ET | 6479 | 3 |
03:27 ET | 5908 | 3.005 |
03:30 ET | 4997 | 3 |
03:32 ET | 4940 | 3.005 |
03:34 ET | 2500 | 3.01 |
03:36 ET | 8462 | 3.015 |
03:38 ET | 926 | 3.025 |
03:39 ET | 4500 | 3.025 |
03:41 ET | 5493 | 3.03 |
03:43 ET | 5771 | 3.025 |
03:45 ET | 14574 | 3.035 |
03:48 ET | 8930 | 3.02 |
03:50 ET | 13416 | 3.01 |
03:52 ET | 19664 | 2.99 |
03:54 ET | 5800 | 2.995 |
03:56 ET | 10646 | 2.99 |
03:57 ET | 28132 | 3.005 |
03:59 ET | 22190 | 3.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 746.5M | -9.6x | --- |
Hillevax Inc | 750.3M | -4.6x | --- |
Scholar Rock Holding Corp | 753.7M | -4.5x | --- |
Mereo BioPharma Group PLC | 596.2M | -16.1x | --- |
CARGO Therapeutics Inc | 766.6M | -5.7x | --- |
Longboard Pharmaceuticals Inc | 720.1M | -8.2x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $746.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.